Pfizer is in value territory, trading at just 10.74X forward earnings with a 5.88% annual dividend yield and over $10 billion in cash after selling $2.4 billion of its HLN position.

Leerink Partners analyst David Risinger has maintained their neutral stance on PFE stock, giving a Hold rating yesterday. David Risinger has ...

Goldman Sachs raises AstraZeneca price target to 16,046 (15,914) pence - 'buy' Barclays raises Standard Chartered price target to 890 (850) pence - 'equal weight' Barclays raises Harbour Energy price ...

Skyrizi had an estimated national TV ad spend of $93.7 million — the highest amount of any brand in the top 10 during this ...

The idea is that if you move your focus to attracting people, you’ll ultimately attract the companies: If you build it (the ...

The acquired portfolio includes Nicotinell, also known as Nicabate in Australia, Thrive in Canada and Habitrol in New Zealand and Canada.

The experts engaged in critical discussions on the gaps in Oral healthcare access, awareness, and empowerment across India. The gathering focused on developing a sustainable and systematic action plan ...

This summary covers recent developments in health news, from Humana's slumping Medicare plan enrollments impacting future ...

Pharmaceutical giant Pfizer Inc. announced on Tuesday that it has reduced its stake in British consumer healthcare company ...

Following a similar move in March, Pfizer is offloading another tranche of Haleon shares. | Pfizer has sold 640 million ...

The latest health news highlights include Kailera Therapeutics' $400 million funding, potential CVS Health restructuring, ...

Pfizer sold a stake in British consumer healthcare group Haleon worth about $3.26 billion on Monday, cutting its shareholding ...